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Abstract
Gender identity disorder (GID, transsexualism) is a multidisciplinary problem of an unclear aetiology. Although the diagnosis of GID is
generally established by psychiatrists, the diagnostic team always includes an endocrinologist, who is responsible for hormonal therapy.
Hormonal therapy is the first step in the sex reassignment procedure and requires careful monitoring in the initial phase and in later years
of treatment.
In this paper we review the latest aspects of the diagnosis and treatment of transsexualism and the most common complications of hor-
monal intervention. (Pol J Endocrinol 2010; 61 (4): 412–416)
Key words: gender identity disorder, transsexualism, diagnosis, hormonal therapy
Streszczenie
Zaburzenie tożsamości płciowej ([GID, grander identity disorder], transseksualizm) jest problemem wielodyscyplinarnym o słabo poznanej
etiologii. Chociaż diagnoza GID jest zasadniczo ustalana przez psychiatrę, w skład zespołu orzekającego zawsze wchodzi endokrynolog,
który odpowiada za prowadzenie terapii hormonalnej. Jest ona pierwszym etapem tak zwanej procedury zmiany płci i wymaga skrupu-
latnego monitorowania w okresie wdrażania, ale także w trakcie jej wieloletniej kontynuacji.
Autorzy zaprezentowali współczesne aspekty diagnostyki i terapii przypadków transseksualizmu oraz najczęstsze powikłania interwen-
cji hormonalnej. (Endokrynol Pol 2010; 61 (4): 412–416)
Słowa kluczowe: zaburzenie identyfikacji płciowej, transseksualizm, diagnoza, terapia hormonalna
Introduction
Gender identity is one of the most important things in
everyone’s life. The individual’s sex is determined by
the genotype, phenotype (including gonadal sex — de-
termined by the internal and external sex organs), en-
docrine and metabolic status, psyche, and birth certifi-
cate sex designation (social sex). Among these “types”
of sex, it is the individual’s psychological sex that deter-
mines his or her gender identity.
Gender identity disorder (GID), often referred to as
transsexualism, may be defined as a discrepancy be-
tween psychological sex and the morphological, biolog-
ical, and social sex, which is often perceived as “non-
self” and belonging to the opposite sex [1].
The available data show that the first sex reassign-
ment surgeries in patients with GID were performed in
the 1920s. Hormonal therapy to complement surgery
was not introduced until 1953 (the case of Christine Jor-
gensen, Denmark). The first male-to-female sex reas-
signment surgery in Poland was performed in 1963 at
the Polish Railways Hospital in Międzylesie while the
first female-to-male sex reassignment surgery in Poland
was performed in 1983.
According to ICD-10, the diagnosis of transsexual-
ism requires the following criteria to be met:
— the desire to live and be accepted as a member of
the opposite sex, usually accompanied by a wish to
make his or her body as congruent as possible with
the preferred sex through surgery and hormone
treatment.
— the transsexual identity has been present persistently
for at least two years.
— the disorder is not a symptom of another mental dis-
order (e.g. schizophrenia) or a chromosomal abnor-
mality.
The highest reported prevalence rates of GID are
1:12,000 for male-to-female (MTF) GID and 1:30,000 for
female-to-male (FTM) GID [2], although data from New
Zealand suggest an even greater scale of the problem
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(1:3639 and 1:22,714, respectively) [3]. Of all the cases of
transsexualism manifested in childhood and adoles-
cence, only 2.5–20.0% persist into adulthood [4].
A distinction should be made between transsexual-
ism and transvestitism. In the latter, the affected indi-
vidual has the desire to experience membership in the
opposite sex (most commonly through clothes) but does
not desire a permanent sex change.
Aetiology
Little is known about the pathogenesis of transsexual-
ism. The possible causes include an interaction of men-
tal, psychological, and somatic (organic) factors. The sig-
nificance of the latter is emphasised by the fact that even
the earliest attempts to exert an external influence on
children (in the first year of life) have proved ineffec-
tive as a therapeutic approach [4, 5]. At the same, time
a more frequent occurrence of emotional disorders, be-
havioural disorders, and other mental disorders in trans-
sexual persons has been demonstrated [6].
The hormonal profile of transsexuals does not dif-
fer significantly from the hormonal profile typical of the
general population. Nevertheless, it was believed that
the development of this disorder might be associated
with a hormonal imprinting of the brain in the foetal
period. This “masculinisation” was believed to be caused
by abnormal maternal levels of hormones. However,
based on the example of individuals with abnormali-
ties of sexual development with the 46 XY karyotype, it
was shown that prenatal exposure to androgens does
not determine male gender identity [7]. Others suggest-
ed the possibility of hormonal resistance limited to the
brain tissue as they did not observe any predisposition
for transsexualism in women with androgen resistance
syndrome [8, 9]. Data supporting the existence of cen-
tral nervous system differentiation in congruence with
the psychological sex have been known for a very long
time [10]. Attempts to explain the nature of transsexual-
ism were also made on the basis of the theory of psycho-
analysis and the theory of learning, examining conflicts
between the mother and child, investigating psycholog-
ical traumas, indicating the causative role of the parents,
and their desire to have a child of the opposite sex.
Diagnosis
According to DSM-IV-TR (The Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, Text-Revised),
two components must be present to make the diagno-
sis. Firstly, there must be evidence of a strong cross-
gender identification, which is the desire to be or the
insistence that one is of the other sex. This cross-gender
identification must not merely be a desire for any per-
ceived cultural advantages of being the other sex. There
must also be evidence of persistent discomfort about
one’s assigned sex or a sense of inappropriateness in
the gender role of that sex. Transsexualism cannot be
diagnosed if the individual has a concurrent physical
intersex condition (e.g. androgen insensitivity syn-
drome or congenital adrenal hyperplasia). Secondly, to
make the diagnosis there must be evidence of clinically
significant distress or impairment in social, occupation-
al, or other important areas of functioning.
Transsexualism may also be suspected in children.
Preoccupation with activities typical of the sex oppo-
site to the individual’s biological sex most commonly
becomes evident between 2 and 4 years of age. In most
cases these phenomena subside during puberty. In
adults the disorder may be a continuation of a previous
condition or develop de novo. Also, in the latter case
spontaneous remissions have been reported.
It is currently believed that the diagnosis of trans-
sexualism should only be made by a psychiatrist. The
differential diagnosis must include, among other abnor-
malities, other personality disorders, schizophrenia, and
paranoid syndromes.
Treatment
The sex reassignment procedure, consisting of hormon-
al therapy and surgery, is one of the management op-
tions in transsexualism. Although it does not guarantee
therapeutic success, it is preferred by the patients. Alter-
natives include psychiatric counselling (individual, fam-
ily, marriage counselling) and psychotherapy, which may
be offered to both children and adults with GID.
The moment in which the sex reassignment proce-
dure in GID should be initiated remains controversial
[4]. According to some clinicians (and many patients),
delaying the sex reassignment decision increases the risk
of neuroses, depression, or suicidal attempts [11]. On
the other hand, due to the possibility of remission dur-
ing puberty, the current guidelines do not recommend
early initiation of hormonal therapy [12].
Undisputable advantages of early, peripubertal ini-
tiation of treatment include the greatest sensitivity of
the target organs to hormonal therapy and the avoid-
ance of voice change, and development of the breasts
and of the appearance of the typical pattern of hair
growth. The drawback is greater complexity of the sur-
gery in MTF GID patients undergoing early hormonal
treatment. One should, however, remember the con-
siderable variability of the moment of reaching psycho-
sexual maturity, when decisions about the selection of
the gender are made in an informed manner.
If treatment is to be conducted in a minor, it should
be commenced at the first signs of puberty (Tanner stage
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2/3) after confirming pubertal levels of sex hormones
[12]. Before the initiation of hormone therapy the pa-
tient must be fully aware of the consequences of sup-
pression treatment and the effects of the sex hormones
(characteristic of the preferred sex) he or she is going to
be administered. The patient should also be informed
about reproduction problems after the treatment and
the limited data on the reversibility of the changes
caused by the suppression of gonadotropin secretion.
One of the arguments against suppressing puberty in
transsexual minors is the potential possibility of disor-
ders of gender identity formation [4].
According to the standards adopted by the World
Professional Association of Transgender Health
(WPATH), each adult should meet the following crite-
ria prior to the initiation of hormone therapy:
— the patient should meet the DSM-IV-TR or ICD-10
diagnostic criteria;
— the patient should be free from mental disorders that
might interfere with the diagnostic or therapeutic
process;
— the patient should be aware of the expected results
of treatment and the benefit-to-risk ratio;
— the patient should have real-life experience living
as the preferred gender for at least 3 months or
should have undergone psychotherapy for a period
prescribed by a psychiatrist or for at least 3 months.
The readiness criteria for hormone therapy in adults
are as follows:
— the patient has functioned in the new role during
real-life experience or psychotherapy;
— the patient has made beneficial changes in coping
with identified problems leading to improving or
continuing stable mental health;
— there is a chance for the patient to use hormone ther-
apy in accordance with the general principles.
The suppression of sex hormone secretion is
achieved by using long-acting GnRH analogues. The
much less commonly used regimens are based on
progestins, antioestrogens, and antiandrogens. Hor-
mone therapy is generally initiated after the age of
16 years.
The aim of the hormone therapy, which is carried
out in parallel with suppression therapy, is to achieve
physiological levels of sex hormones of the preferred
gender. The treatment regimens do not differ significant-
ly from those used in hypogonadism. In young patients
with the diagnosis of FTM transsexualism, the risk of
growth suppression by androgens is taken into account
(which is why oxandrolone is the preferred agent).
The standard doses of male sex hormones used in
the management of transsexualism are as follows:
160–240 mg/d p.o. for testosterone undecylate (Undestor,
Testocaps), 100–200 mg i.m. q2w or 50–100 mg i.m. qw
for testosterone heptanoate (Testosteronum prolonga-
tum), 1000 mg for testosterone undecylate i.m. q12w
(Nebido), 2.5–10 g/d for testosterone 1–2% gel (Andro-
top, Tostran), or 2.5–7.5 mg/d for testosterone patches.
Testosterone levels should be monitored: in the middle
of the interval between the hormone injections (for tes-
tosterone heptanoate), prior to the next injection (for
testosterone undecylate), at any time point after one
week of using the transdermal formulation, and
3–5 hours following the intake of the oral formulation of
testosterone undecylate. The concentration of testoster-
one should be within 350–700 ng/dL, and that of estra-
diol below 50 pg/mL. In MTF transsexualism, estradiol
is used at the dose of 2–6 mg/d p.o., 0.1–0.4 mg biw in
the transdermal formulation, or 2–20 mg i.m. q1w–q2w.
The aim is to achieve estradiol levels below 200 pg/mL
(734 pmol/L) and total testosterone levels below 55 ng/dL
(1.9 nmol/L). Oestrogen therapy in MTF transsexualism
may lead to growth limitation, which may be a plus side.
The first effects of therapy in the form of reduced
libido and a decrease in spontaneous erections may
appear as early as within 4 weeks, while fat redistribu-
tion, muscle mass reduction, and changes in the appear-
ance of the skin are observed within 3–6 months of treat-
ment initiation. A decrease in testicular volume and
growth of the breasts may be expected within a similar
timeframe, which is why breast augmentation surgery
is not generally considered before the lapse of 2 years
of oestrogen therapy. Semen production and terminal
hair growth may not decrease until 3 years of treatment.
In MTF transsexualism the following antiandrogens are
commonly used: spironolactone 100–200 mg/d and
cyproterone acetate 50–100 mg/d.
During the first year of hormone therapy, follow-
up medical examinations should be conducted every
3 months. They should include an anthropometric as-
sessment, sexual maturation assessment, blood pressure
measurement, and determination of gonadotropin, tes-
tosterone and estradiol levels.
In subsequent years the frequency of visits may be
reduced to 1–2 annually. Laboratory monitoring, in
addition to full blood counts, liver and renal function
tests, lipid profile, and carbohydrate metabolism param-
eters (glucose, glycated haemoglobin), gonadotropin
and sex steroid levels should also include prolactin lev-
els in MTF transsexualism and BMD calculation if risk
factors for fractures are present (particularly after con-
clusion of hormone therapy in gonadectomised pa-
tients). Patients with FTM and MTF transsexualism
should also undergo routine screening for breast and
cervical cancers (if these organs are intact) and for pros-
tate cancer, respectively [12].
Surgical transformation of the external genitalia and
gonadectomy are performed after the patient reaches
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legal age. This treatment is conditional upon the pa-
tient’s informed decision, feeling comfortable in the new
social role, and good results of at least 12 months of
hormone therapy. Experts suggest that everyday func-
tioning as the preferred gender for at least a year (the
so-called real-life experience) is a prerequisite for the
decision to undergo irreversible surgery. In FTM trans-
sexualism, hysterectomy is always considered in addi-
tion to ovariectomy [12], as this way the potential risk
of endometrial cancer is reduced.
In addition to gonadectomy, surgical procedures in
MTF transsexualism also include penectomy (the clitoris
is formed from the glans penis), formation of the vagina
from the penile skin, and formation of the labia from the
scrotal skin. Excess hair is removed by electrolysis or la-
ser treatment. FTM transsexualism is a much greater chal-
lenge for the surgical team and involves a multistage pro-
cedure. The scrotum is formed from the labia majora.
Erection of the surgically formed penis requires implan-
tation of mechanical devices. Mastectomy is performed
as a standard procedure [12]. It should be emphasised
that in the Polish legal environment, the real-life experi-
ence, although definitely justified from a theoretical and
practical point of view, should be preceded by changing
the birth certificate sex designation (which is undisput-
ed in the case of surgical treatment).
Side effects of hormone therapy
Many questions concerning hormone therapy of GID
cannot be answered unequivocally. It has not been es-
tablished whether hormone therapy should be contin-
uous or whether it should be discontinued at some
point. It is unknown whether the standard recommen-
dations for the postmenopausal period should be im-
plemented upon reaching a certain age in the case of
MTF GID. Similarly, there are no management algo-
rithms for FTM transsexual persons who are unwilling
to discontinue therapy [13].
There have been reports, for instance, of the in-
creased risk of polycystic ovary syndrome following
hormone therapy in FTM transsexuals [14]. Such sug-
gestions have been reported in Dutch studies [15].
There have also been reports of a significantly in-
creased risk of venous thromboembolism (VTE) in GID
[16]. The risk of VTE is much higher in MTF transsexu-
als taking ethinyl estradiol orally compared to individ-
uals taking 17-b estradiol via the transdermal route.
Androgen therapy in FTM transsexuals exerts anti-
thrombotic effects [17]. It should be noted that an anal-
ysis of 251 cases of transsexualism (with duration of
hormone therapy of 64.2 ± 38.0 months) failed to con-
firm the increased risk of thrombosis [18].
Although concern has been raised about the poten-
tial development of an atherogenic lipid profile during
hormone therapy in FTM transsexuals, no such risk has
been demonstrated in clinical observations so far [19].
The authors of a review paper on 712 cases of FTM trans-
sexualism followed up for 29 years demonstrated ele-
vated levels of kallikreins, endothelin-1, CRP, and ho-
mocysteine during androgen therapy (250 mg of test-
osterone esters i.m. q2w–q3w). No changes in insulin
sensitivity, fibrinolysis parameters, von Willebrand fac-
tor, interleukin-6, arterial wall rigidity, and blood pres-
sure have been observed [15]. The study also showed
no bone mineral density (BMD) loss during treatment,
while other data suggest, for example, an increase in
femoral neck BMD from 1.068 to 1.109 g/cm2 during two
years of treatment with oestrogens in MTF transsexu-
als [20]. One of the recently published studies evaluat-
ing the safety of a long-acting intramuscular testoster-
one formulation demonstrated, over 3 years of follow-
up, a reduction in cholesterol levels from 218 ± 47 to
188 ± 42 mg/dL unaccompanied by any changes in HDL
or triglyceride levels. During the same period the sub-
jects developed increases in haemoglobin and haemat-
ocrit (typical of androgen therapy), which were still
within physiological limits [21].
The potential likelihood of increasing the risk of can-
cer as a result of hormone therapy remains unclear. It is
noteworthy that patients with MTF GID generally re-
ceive higher doses of hormones than typical patients
with hypogonadism. In addition, the fact that hormone
therapy is most commonly prescribed after 50–60 years
of age may be of additional significance [13].
Despite the lack of certain evidence, it is suggested
that oestrogen therapy of MTF GID may stimulate the
development of prolactinoma [22]. Elevated prolactin
levels in MTF transsexuals are demonstrated in 1 in
5 cases, which is why these patients are encouraged to
have their prolactin levels checked every 1–2 years.
As far as androgen therapy of FTM transsexuals is
concerned, one must not forget about the partial arom-
atisation of androgens to oestradiol. Although the rela-
tionship between androgen therapy and breast cancer
is uncertain, once case has been reported in an FTM
GID patient with residual gland tissue after mastecto-
my [23]. Japanese authors analysed samples of the gland
tissue collected from 186 FTM transsexual individuals
in terms of previous exposure to androgen therapy.
Based on the comparison of the histopathological pic-
ture, they concluded that hormone therapy did not af-
fect the risk of breast cancer [24].
There have also been reports of prostate cancer in
MTF transsexuals (the prostate is not routinely resected
during sex reassignment surgery) [25] and ovarian can-
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cer in FTM GID patients receiving hormone therapy
(prior to ovariectomy) [26].
The side effects of hormone therapy in MTF trans-
sexual patients also include: elevated liver enzymes,
cholelithiasis, depression, reduced haemoglobin, and
reduced IGF-1. The side effects seen in FTM transsexu-
al individuals include, among others, acne, weight gain,
sleep apnoea syndrome, aggression, hypersexuality,
increased IGF-1, and reduced BMD following gonadec-
tomy [27].
Conclusions
Hormone therapy is an integral element of management
in patients with gender identity disorder. The aim of
the treatment is to suppress the secretion of hormones
characteristic of the patient’s biological sex and to
achieve appropriate levels of sex hormones character-
istic of the preferred sex. An important part of the pro-
cedure is a thorough analysis of the potential complica-
tions of hormone therapy.
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